Zynex, a leader in non-invasive medical technology, has announced FDA clearance for its latest device, the TensWave. This new device is specifically designed to address the needs of patients and insurance providers who only cover Transcutaneous Electrical Nerve Stimulation (TENS) therapy.

The TensWave is a prescription-only, portable, and user-friendly device that delivers effective pain relief through TENS therapy. This clinically proven method has been shown to alleviate both chronic and acute pain without the need for medication. While the TensWave offers a focused solution for TENS therapy, it is not intended to replace Zynex's flagship product, the NexWave electrotherapy device. Instead, it provides an additional option that caters to patients with specific insurance coverage limitations.

By introducing the TensWave, Zynex reinforces its commitment to innovation in pain management. The company continues to develop advanced solutions that improve the quality of life for individuals suffering from pain. This latest addition to their product portfolio further solidifies Zynex's position as a leading provider of non-invasive pain management solutions.

The TensWave offers several benefits to patients:

• Effective pain relief: TENS therapy has been proven to effectively alleviate pain.
• Non-invasive: The device does not require surgery or injections.
• User-friendly: The portable design allows for easy integration into daily routines.
• Prescription-only: Ensures proper usage and optimal results.

By offering a wider range of devices, Zynex empowers healthcare providers to offer tailored treatment options to their patients. This approach not only improves patient outcomes but also enhances the overall value proposition for both patients and healthcare providers.

With the FDA clearance of the TensWave, Zynex continues to lead the way in providing innovative and effective solutions for pain management.